SCHEMBL3732869

SCHEMBL3732869

COc1ccc(CCC(N)c2ccc(OC)c(OC)c2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C19 P33261 1/20 0.51
KDM4E B2RXH2 4/20 0.47
MAPT P10636 3/20 0.47
ALDH1A1 P00352 2/20 0.47
ESR2 Q92731 1/20 0.47
HSD17B10 Q99714 1/20 0.47
STAT3 P40763 1/20 0.47
CYP19A1 P11511 1/20 0.46
TUBB4A P04350 1/20 0.46
TUBB P07437 1/20 0.46
TUBA3C P0DPH7 1/20 0.46
TUBA1B P68363 1/20 0.46
TUBA4A P68366 1/20 0.46
TUBB4B P68371 1/20 0.46
TUBB3 Q13509 1/20 0.46
TUBB2A Q13885 1/20 0.46
TUBB8 Q3ZCM7 1/20 0.46
TUBA3E Q6PEY2 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3739107 0.87 ADRB2 (0.46) KDM4EMAPTALDH1A1STAT3CYP19A1
SCHEMBL28103034 0.87 LMNA (0.48) MAPTNPSR1L3MBTL1TDP1LMNA
SCHEMBL3732696 0.83 PPARA (0.47) KDM4ESTAT3CYP19A1MAPK1ATM
SCHEMBL9274784 0.79 STAT3 (0.54) CYP1A2CYP2D6KDM4ESTAT3CYP19A1
SCHEMBL10934457 0.79 ALDH1A1 (0.38) CYP1A2CYP2D6CYP2C19KDM4EMAPT
SCHEMBL3734743 0.79 CYP1A2 (0.58) CYP1A2CYP2D6CYP2C19KDM4EMAPT
SCHEMBL26670732 0.79 CA12 (0.47) CYP1A2CYP2D6CYP2C19MAPTTUBB4A
SCHEMBL3735109 0.79 CYP1A2 (0.58) CYP1A2CYP2D6CYP2C19KDM4EMAPT
SCHEMBL3734984 0.79 CYP1A2 (0.58) CYP1A2CYP2D6CYP2C19KDM4EMAPT
SCHEMBL1162783 0.78 CYP1A2 (0.57) CYP1A2CYP2D6CYP2C19KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2114867-B1 AMINOAMIDES AS OREXIN ANTAGONISTS HOFFMANN LA ROCHE (CH) 2012-12-12 EP disclosed
US-7829563-B2 Aminoamides as orexin antagonists HOFFMANN-LA ROCHE INC. (US) 2010-11-09 US disclosed
EP-2114867-A1 AMINOAMIDES AS OREXIN ANTAGONISTS F. Hoffmann-Roche AG (CH) 2009-11-11 EP disclosed
WO-2008107335-A1 AMINOAMIDES AS OREXIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2008-09-12 WO disclosed
US-20080221166-A1 AMINOAMIDES AS OREXIN ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2008-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221166-A1 AMINOAMIDES AS OREXIN ANTAGONISTS HCRTR1, HCRTR2, HRH3 CYP1A2 1026/4885CYP2D6 2773/4885CYP2C19 2235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.